Evidence map›Paper›PMID 20703251›Full record

ReviewNature reviews. Cancer2010

Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research.

R William G Watson, Elaine W Kay, David Smith

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Cancer biomarker discovery and validation.Translational cancer research · 2015
    Article
  10. Improving diversity in cancer research trials: the story of the Cancer Disparities Research Network.Journal of cancer education : the official journal of the American Association for Cancer Education · 2014
    Article
  11. Article
  12. Biopsies: next-generation biospecimens for tailoring therapy.Nature reviews. Clinical oncology · 2013
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

R William G WatsonUCD School of Medicine and Medical Science, University College Dublin, Ireland. william.watson@ucd.ie
Elaine W Kay
David Smith

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is caused by complex interactions between genes, environment and lifestyles. Biobanks of well-annotated human tissues are an important resource for studying the underlying mechanisms of cancer. Although such biobanks exist, their integration to form larger biobanks is now required to provide the diversity of samples that are needed to study the complexity and heterogeneity of cancer. Clear guidelines and policies are also required to address the challenges of integrating individual institutional or national biobanks and build public trust. This Science and Society article highlights some of the main practical and ethical issues that are undergoing discussion in the integration of tissue biobanks for cancer.

Indexed as

Bioethical IssuesEthics, ResearchNeoplasmsAnimalsBiological Specimen BanksGuidelines as TopicHumans

Identifiers

PMID20703251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.